Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once‐daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hepatology
Autors principals: Reau, Nancy, Kwo, Paul Y., Rhee, Susan, Brown, Robert S., Agarwal, Kosh, Angus, Peter, Gane, Edward, Kao, Jia‐Horng, Mantry, Parvez S., Mutimer, David, Reddy, K. Rajender, Tran, Tram T., Hu, Yiran B., Gulati, Abhishek, Krishnan, Preethi, Dumas, Emily O., Porcalla, Ariel, Shulman, Nancy S., Liu, Wei, Samanta, Suvajit, Trinh, Roger, Forns, Xavier
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220874/
https://ncbi.nlm.nih.gov/pubmed/29672891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30046
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars